Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 282

1.

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.

Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, Hosohata K, Ushijima K, Fujimura A.

Clin Pharmacol Ther. 2011 Feb;89(2):229-33. doi: 10.1038/clpt.2010.268. Epub 2010 Dec 22.

PMID:
21178986
2.

Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.

Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T.

Circ J. 2009 Aug;73(8):1498-503. Epub 2009 Jun 17.

3.

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.

Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneetrithep B, Likidlilid A.

PLoS One. 2014 Oct 16;9(10):e110188. doi: 10.1371/journal.pone.0110188. eCollection 2014.

4.

Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.

Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.

Clin Pharmacol Ther. 2011 Aug;90(2):287-95. doi: 10.1038/clpt.2011.127. Epub 2011 Jun 29.

PMID:
21716274
5.
6.

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA.

JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.

7.

Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.

Chen BL, Zhang W, Li Q, Li YL, He YJ, Fan L, Wang LS, Liu ZQ, Zhou HH.

Clin Exp Pharmacol Physiol. 2008 Aug;35(8):904-8. doi: 10.1111/j.1440-1681.2008.04915.x. Epub 2008 Mar 13.

PMID:
18346178
8.

The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.

Liu Q, Dang DS, Chen YF, Yan M, Shi GB, Zhao QC.

Genet Test Mol Biomarkers. 2012 Nov;16(11):1293-7. doi: 10.1089/gtmb.2012.0119. Epub 2012 Oct 9.

PMID:
23046071
9.

CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.

Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ, Zou JJ.

Pharmazie. 2013 Mar;68(3):183-6.

PMID:
23556336
10.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
12.

Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.

Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, Kim JS, Shin ES, Chang CW, Lee JE, Jang Y.

Am J Cardiol. 2009 Jul 1;104(1):46-51. doi: 10.1016/j.amjcard.2009.02.045. Epub 2009 May 4.

PMID:
19576320
13.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
14.

CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.

Mejin M, Tiong WN, Lai LY, Tiong LL, Bujang AM, Hwang SS, Ong TK, Fong AY.

Int J Clin Pharm. 2013 Aug;35(4):621-8. doi: 10.1007/s11096-013-9783-y. Epub 2013 May 10.

PMID:
23661171
15.

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2010 Jun 1;55(22):2427-34. doi: 10.1016/j.jacc.2010.02.031.

16.

Prediction of clopidogrel low responders by a rapid CYP2C19 activity test.

Tazaki J, Jinnai T, Tada T, Kato Y, Makiyama T, Ikeda T, Yamane K, Naruse Y, Takahashi K, Watanabe H, Kimura T, Horiuchi H.

J Atheroscler Thromb. 2012;19(2):186-93. Epub 2011 Dec 14.

17.

Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.

Subraja K, Dkhar SA, Priyadharsini R, Ravindra BK, Shewade DG, Satheesh S, Sridhar MG, Narayan SK, Adithan C.

Eur J Clin Pharmacol. 2013 Mar;69(3):415-22. doi: 10.1007/s00228-012-1381-8. Epub 2012 Sep 6.

PMID:
22955794
18.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

19.

Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.

Arya V, Mahajan P, Saraf A, Mohanty A, Sawhney JP, Bhargava M.

Int J Lab Hematol. 2015 Dec;37(6):809-18. doi: 10.1111/ijlh.12416. Epub 2015 Aug 12.

PMID:
26264906
20.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445

Supplemental Content

Support Center